In adjuvanted recombinant subunit vaccines, monophosphoryl lipid A is co-formulated at a human dose of 50 µg per 0.5 mL either adsorbed onto 500 µg aluminium hydroxide or incorporated into a liposomal system with 50 µg QS-21 in the same 0.5 mL injection volume. Aluminium hydroxide binding is pH-dependent because the lipid A phosphate groups interact with the adjuvant surface at a formulation pH between 6.5 and 7.4; phosphate-containing buffers must therefore be introduced only after the adsorption step, since free phosphate above 10 mM competes for surface ligand exchange. For liposomal presentations, the lipid components are dissolved in ethanol or chloroform, dried to a thin film, hydrated with phosphate-buffered saline at 60–65°C, and reduced in size by high-pressure homogenisation at 10,000–15,000 psi for 3–5 passes. The resulting dispersion is analysed by dynamic light scattering under ISO 22412:2017 to confirm a Z-average below 120 nm and a polydispersity index not exceeding 0.20 before sterile filtration through a 0.45 µm prefiltration membrane and then a 0.22 µm sterilising-grade PVDF membrane. Aseptic filling into vials or prefilled syringes is performed in ISO 14644-1:2015 Class 5 cleanrooms. The filled product is tested for subvisible particles under USP <788> Method 1; acceptance limits are not more than 6,000 particles ≥ 10 µm and not more than 600 particles ≥ 25 µm per container. Visible particulates are controlled against USP <790>. Because MPLA is a TLR4 agonist, the rabbit pyrogen test of USP <151> or Ph. Eur. 2.6.8 is preferred over the Limulus amebocyte lysate test when endotoxin interference is observed, and the release limit is set by the product monograph rather than by routine endotoxin limit assumptions.

What Limits Dispersed-Phase Homogeneity When MPLA Is Wet-Granulated with Mannitol?

For oral granules and tablets, MPLA is typically present at microgram levels per unit, so the primary process risk is not dissolution rate but content uniformity and segregation. The API is first dispersed in a 5% w/w hypromellose E5 binder solution in purified water, and the suspension is sprayed onto a mannitol–microcrystalline cellulose bed in a high-shear granulator with a 10 L bowl. Impeller tip speed is maintained between 4 m/s and 8 m/s while the chopper runs at 1,500 rpm; granulation endpoint is determined by torque rise and visual consistency rather than fixed time. Wet granules are dried in a fluid-bed dryer at 55–65°C inlet air to a final loss on drying of 1.0–2.0%, then milled through a 0.8 mm screen. Dried granule size is checked by sieve analysis with a target D50 of 150–250 µm. Compression is carried out on a rotary tablet press with paddle feeder speed 20–40 rpm; tablet breaking force is specified at 60–100 N according to USP <1217>. Uniformity of dosage units is tested under USP <905> with an acceptance value not exceeding 15.0. Dissolution is run in USP Apparatus II at 50 rpm in pH 6.8 phosphate buffer, with a Q value established during early development because no pharmacopeial monograph for MPLA oral solids currently defines a universal acceptance criterion. Published stability data for MPLA in oral solid matrices are limited; therefore dryer inlet temperature above 65°C is avoided and the granulation process is performed under nitrogen sweep where practical to reduce oxidative degradation of lipid acyl chains.

Delayed-Release Coating Thresholds for Enteric Capsule Fill

When MPLA is formulated for oral mucosal antigen delivery to the distal ileum, enteric protection is applied to hard capsules or tablet cores. The coating is prepared as a 20% w/w aqueous dispersion of methacrylic acid-ethyl acrylate copolymer type C, plasticised with triethyl citrate at 10–20% of polymer solids, and sprayed in a perforated coating pan with inlet air temperature 45–55°C, product temperature 28–32°C, atomising air pressure 1.0–1.5 bar, and spray rate 4–8 g/min. A dry polymer weight gain of 10–12% is used as a starting point; coat thickness and pore-free film formation are confirmed by scanning electron microscopy on cross-sectioned units. Delayed-release disintegration is tested under USP <701> using 0.1 N hydrochloric acid for 2 h, during which no unit disintegrates, followed by pH 6.8 phosphate buffer for 45 min, where complete disintegration is required. Capsule shells are low-moisture hypromellose with a shell moisture specification of 5–8% to reduce film cracking during storage. For granule-filled capsules, the fill weight is controlled to ± 3% of target and the granule angle of repose is kept below 35° to maintain reproducible dosing on a dosator or tamping-pin capsule machine. Published data for MPLA enteric-coated oral vaccine prototypes remain limited; the parameters above are derived from standard oral solid dose coating practice and should be qualified for each MPLA-containing formulation because the lipid A congener may alter film adhesion on lipophilic granule surfaces.

Subcutaneous allergy immunotherapy suspensions containing MPLA as a TLR4 agonist are formulated with modified allergen tyrosine adsorbates to reduce allergenicity while retaining immunogenicity. The product is a sterile suspension for injection, typically filled at 0.5 mL into single-dose prefilled syringes, and the marketed product literature indicates microgram-level MPLA content per dose; exact commercial release limits are proprietary. Resuspension before administration is performed by gentle inversion, not vigorous shaking, because high shear disrupts the tyrosine-adsorbed allergen/adjuvant particle and changes sedimentation behaviour. Suspension quality is controlled by visual appearance and particle-size microscopy; subvisible particulate matter is tested under USP <788>, and visible particles under USP <790>. Sterility is verified by membrane filtration under USP <71>, and pyrogenicity by the rabbit pyrogen test under USP <151> because MPLA can interfere with LAL-based endotoxin assays. The manufacturing process for this route does not use terminal sterilisation; aseptic filling into syringes is performed under ISO 14644-1:2015 Class 5 conditions. Process capability data from suspension filling lines indicate that in-process checks for fill volume, resuspendability, and tip cap integrity are more sensitive to batch rejection than chemical assay of the low-dose MPLA component alone.

When Lyophilization Is Specified for MPLA Injectable Cakes

Freeze-dried MPLA presentations require collapse temperature data from freeze-drying microscopy rather than differential scanning calorimetry alone, because the lipid adjuvant modifies the freeze-concentrate microstructure. For a representative formulation containing 5% w/v trehalose dihydrate and 1% w/v sucrose, collapse temperature is typically observed between -32°C and -35°C; annealing at -20°C for 2–4 h is used to complete crystallisation of bulking components and reduce ice crystal heterogeneity across the shelf. Primary drying is run at a shelf temperature of -25°C and a chamber pressure of 100–150 mTorr for 24–48 h, followed by secondary drying at +25°C to +30°C for 6–12 h. Residual moisture is determined by Karl Fischer titration according to USP <921>, with a release limit of ≤ 1.0%. Reconstitution with water for injection must be complete within 2 min without visible aggregates; the reconstituted particle size is measured by dynamic light scattering under ISO 22412:2017. A Z-average shift of more than 20 nm relative to the pre-lyophilisation dispersion is treated as indicative of aggregation or vesicle fusion and fails the batch. Cake appearance is evaluated as uniform and intact, with no melt-back, shrink, or collapse at the container wall. Lyophilisation cycle robustness is assessed by batch-to-batch comparison of cake resistance and primary drying time; vials in the centre of the shelf frequently dry 10–20% slower than edge vials due to radiative heat differences, and this gradient is used to set the conservative primary drying endpoint. Published freeze-drying data for MPLA liposomes are limited to research formulations; the cycle values above are representative for liposomal products and require formulation-specific qualification.

Liposomal MPLA is processed by high-pressure homogenisation after coarse dispersion in a rotor-stator mixer operating at 8,000–12,000 rpm for 15–30 min. The coarse dispersion is then passed through a piston-gap homogeniser at 10,000–15,000 psi for 3–5 discrete passes with a heat exchanger maintaining product temperature at 20–25°C to prevent phospholipid degradation and MPLA acyl chain oxidation. A representative research lipid composition includes dioleoylphosphatidylcholine and cholesterol at a phospholipid:cholesterol molar ratio near 4:1 with MPLA at 5–10 mol%; final commercial liposomal adjuvant compositions are proprietary. The homogenised dispersion is characterised by dynamic light scattering under ISO 22412:2017, and zeta potential is measured by electrophoretic light scattering under ISO 13099-1:2012 to confirm a formulation-specific negative surface charge generated by the lipid A phosphate groups. Inclusion efficiency is determined by separating free MPLA from liposome-associated MPLA using ultracentrifugation at 100,000 × g for 1 h and quantifying the supernatant by reversed-phase HPLC with charged aerosol detection. The liposome formulation is sterile-filtered through a 0.22 µm PVDF membrane only when the Z-average is below 120 nm; larger vesicles require pre-filtration through 0.45 µm or a switch to aseptic processing. Batch-to-batch variance in homogenisation is primarily governed by piston seal wear and product temperature drift, not by phospholipid lot variability, when the same cholesterol source is used.

Release Testing for MPLA Dosage Forms Is Not Limited to Sterility and Endotoxin

MPLA-containing dosage forms require a matrix of release tests that differ by route and physical form. For injectable lyophilised or suspension presentations, sterility under USP <71>, pyrogenicity under USP <151> or Ph. Eur. 2.6.8, particulate matter under USP <788>, and container closure integrity under USP <1207> are mandatory. For oral tablets and capsules, dosage-unit uniformity under USP <905>, disintegration or dissolution under USP <701> or USP <711>, and water content under USP <921> are applied. MPLA identity and assay are frequently quantified by HPLC with charged aerosol detection because the lipid A congener lacks a strong UV chromophore; acceptable assay ranges are typically 90.0–110.0% of label claim unless a product monograph states otherwise.